Stock Financial Ratios, Dividends, Split History

DE / Deere & Co. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price137.58
Volume5,113,900.00
Market Cap ($M)44,540.26
Enterprise Value ($M)67,746.17
Book Value ($M)10,410.30
Book Value / Share32.10
Price / Book4.81
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 323,300,000
Weighted Average Number Of Shares Outstanding Basic 319,500,000
Common Shares Outstanding 322,595,010
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.04
Return on Equity (ROE)0.33
Balance Sheet (mrq) ($M)
Assets69,873.00
Liabilities59,438.40
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Financial Services Revenue2,731,500,000.00
Sales Revenue Goods Net25,885,100,000.00
Revenues29,737,700,000.00
Revenue From Related Parties84,000,000.00
Sales Revenue Services Net288,000,000.00
Operating Income3,543.00
Net Income2,159.20
Earnings Per Share Basic6.76
Earnings Per Share Diluted6.68
Cash Flow Statement (mra) ($M)
Cash From Operations2,199.80
Cash from Investing-1,644.30
Cash from Financing-1,644.30
Identifiers and Descriptors
CUSIP244199105
Central Index Key (CIK)315189
Related CUSIPS
244199955 244199905 024419910

Split History

Stock splits are used by Deere & Co. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

4h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Related News Stories

Stocks To Watch: Prime Time In Retail

2018-07-14 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (285-0)

8 Top Picks From Credit Suisse With Implied Upside of 50% or More

2018-07-12 247wallst
Investors have been finding it harder to generate positive returns in 2018 than in 2017 and the few prior years. The bull market is effectively nine years old, and trade wars, rising interest rates and a slowdown in some of the expectations of global growth are some of the variables making it more difficult for investors to decide how to best position their investment portfolio. (4-0)

The 20 Stocks From Goldman Sachs' Buy List That You Should Actually Consider | InvestorPlace

2018-07-11 investorplace
But recently, the equity research team at Goldman compiled a list of stocks within the company’s coverage universe that have the most potential upside to their price targets. The list is long (about 40 stocks), and Goldman pegs all of them as having roughly 30% or more upside to their price target. (28-0)

Deere: We're Intrigued

2018-07-04 seekingalpha
A few weeks ago, we recognized Deere's growth potential but did not see much risk to the upside, and we recommended holding the name.

Book Review: 'Nourished Planet' Editor, Danielle Nierenberg, Island Press, 2018

2018-07-03 seekingalpha
As the human family increases toward 10 billion, the chemical-agricultural industrial food system, based on monoculture crops and meat diets, is proving unsustainable. (4-0)

CUSIP: 244199105